S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:BIOL

BIOLASE (BIOL) Competitors

$1.62
+0.03 (+1.89%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.57
▼
$1.70
50-Day Range
$1.59
▼
$675.00
52-Week Range
$1.56
▼
$269.27
Volume
156,598 shs
Average Volume
134,208 shs
Market Capitalization
$1.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$513.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BIOL vs. BBLG, OPGN, ALLR, RSLS, AKAN, SQZ, INFI, MOTS, NBY, and SCPS

Should you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Bone Biologics (BBLG), OpGen (OPGN), Allarity Therapeutics (ALLR), ReShape Lifesciences (RSLS), Akanda (AKAN), SQZ Biotechnologies (SQZ), Infinity Pharmaceuticals (INFI), Motus GI (MOTS), NovaBay Pharmaceuticals (NBY), and Scopus BioPharma (SCPS). These companies are all part of the "medical" sector.

BIOLASE vs.

Bone Biologics (NASDAQ:BBLG) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation.

Bone Biologics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Bone Biologics has a net margin of 0.00% compared to Bone Biologics' net margin of -57.00%. BIOLASE's return on equity of -123.42% beat Bone Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bone BiologicsN/A -123.42% -82.63%
BIOLASE -57.00%-345.58%-71.24%

In the previous week, BIOLASE had 3 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for BIOLASE and 0 mentions for Bone Biologics. BIOLASE's average media sentiment score of 0.00 beat Bone Biologics' score of -0.01 indicating that Bone Biologics is being referred to more favorably in the media.

Company Overall Sentiment
Bone Biologics Neutral
BIOLASE Neutral

Bone Biologics has higher earnings, but lower revenue than BIOLASE. Bone Biologics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bone BiologicsN/AN/A-$1.49M-$9.20-0.08
BIOLASE$48.46M0.04-$28.63M-$264.93-0.01

BIOLASE has a consensus price target of $513.50, indicating a potential upside of 32,205.76%. Given Bone Biologics' higher probable upside, analysts plainly believe BIOLASE is more favorable than Bone Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bone Biologics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
BIOLASE
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

BIOLASE received 286 more outperform votes than Bone Biologics when rated by MarketBeat users.

CompanyUnderperformOutperform
Bone BiologicsN/AN/A
BIOLASEOutperform Votes
286
57.55%
Underperform Votes
211
42.45%

Summary

BIOLASE beats Bone Biologics on 8 of the 13 factors compared between the two stocks.


Get BIOLASE News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOL vs. The Competition

Export to Excel
MetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$1.70M$1.53B$4.35B$6.28B
Dividend YieldN/A1.65%5.83%9.76%
P/E Ratio-0.018.63113.4811.58
Price / Sales0.040.782,955.9856.07
Price / CashN/A12.0721.3522.67
Price / Book0.032.613.804.74
Net Income-$28.63M$21.82M$121.13M$185.40M
7 Day Performance-16.03%-3.01%107.62%1.56%
1 Month Performance-66.78%-16.15%108.88%-0.74%
1 Year Performance-99.37%-17.53%129.14%5.94%

BIOLASE Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBLG
Bone Biologics
1.4121 of 5 stars		$0.71
-4.1%		N/AN/A$2.22MN/A-0.082Positive News
Gap Down
OPGN
OpGen
0 of 5 stars		$0.25
+13.6%		N/A-40.9%$2.23M$2.82M-0.0285Analyst Report
News Coverage
Gap Down
ALLR
Allarity Therapeutics
0 of 5 stars		$0.82
-7.8%		N/A-100.0%$2.25MN/A0.0014
RSLS
ReShape Lifesciences
1.6815 of 5 stars		$0.65
-5.8%		$8.00
+1,126.4%		-96.3%$2.25M$11.24M0.0040Gap Up
AKAN
Akanda
0 of 5 stars		$0.61
-18.6%		N/A-88.6%$2.09M$2.62M0.0046Positive News
Gap Down
SQZ
SQZ Biotechnologies
1.658 of 5 stars		$0.08
+14.9%		$77.50
+100,549.4%		-99.6%$2.27M$18.16M-0.0353Gap Down
INFI
Infinity Pharmaceuticals
1.7519 of 5 stars		$0.02
flat		$1.50
+6,626.5%		-98.2%$2.02M$2.59M-0.0530Gap Down
MOTS
Motus GI
2.0679 of 5 stars		$0.49
-2.0%		$3.71
+655.0%		-80.7%$2.39M$556,000.00-0.1343Positive News
Gap Down
NBY
NovaBay Pharmaceuticals
0 of 5 stars		$0.46
-6.1%		N/AN/A$1.94M$14.40M-0.0529Gap Down
SCPS
Scopus BioPharma
0 of 5 stars		$0.05
+28.0%		N/A-78.7%$1.92MN/A0.0013Gap Up

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:BIOL) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -